Immune checkpoint blockade, including anti-PD-1 and anti-CTLA-4 therapy, has brought effective and sustainable benefits to late-stage melanoma patients, with a response rate of approximately 30% 2, and MAPK inhibition therapy was reported to be effective in approximately 50% of melanomas with a BRAF mutation 3. The gene discussed is CTLA4; the disease is melanoma.